Suspected Prosthetic Valve Thrombosis
Mechanical or bioprosthetic valve with suspected thrombus
All Pathways
Cardiothoracic SurgeryEmergency
Prosthetic Valve Thrombosis Management (ACC/AHA 2020)
Prosthetic Valve Thrombosis Management (ACC/AHA 2020): Suspected Prosthetic Valve Thrombosis → Clinical Presentation → Diagnostic Workup → Obstructive o...
Pathway Overview
11 steps
Algorithm Steps
11 total
01Start 02Action Clinical Presentation
Recognize PVT signs
- SYMPTOMS:
- • New dyspnea / heart failure
- • Embolic event (stroke, limb ischemia)
- • Syncope
- • New murmur (change in prosthetic sounds)
- RISK FACTORS:
- • Subtherapeutic anticoagulation (most common)
- • Older-generation valves
- • Mitral position (higher risk)
03Action Diagnostic Workup
TEE is gold standard
- TTE: initial screening
- • Elevated gradients (compare to baseline)
- • Decreased leaflet motion
- TEE: REQUIRED for diagnosis (Class I)
- • Direct visualization of thrombus
- • Thrombus size measurement
- • Differentiate thrombus vs pannus
- Fluoroscopy: assess leaflet motion
04Decision Obstructive or Non-Obstructive?
Key determinant of urgency
- OBSTRUCTIVE:
- • High gradients
- • Reduced effective orifice area
- • Hemodynamic compromise
- NON-OBSTRUCTIVE:
- • Normal gradients
- • Small thrombus <10mm
- • Found incidentally or on surveillance
05Action Obstructive PVT
Requires urgent intervention
- TWO OPTIONS:
- 1. SURGERY (Class I if available):
- • Valve replacement/thrombectomy
- • Preferred for large thrombus
- • Lower embolic risk
- 2. THROMBOLYSIS:
- • When surgery high-risk/unavailable
- • Embolic risk 10-15%
- • See contraindications
06Action Surgical Intervention
Valve surgery for PVT
- OPTIONS:
- • Thrombectomy (if valve salvageable)
- • Valve re-replacement (most common)
- INDICATIONS (Class I):
- • Large thrombus (>10mm)
- • Mobile thrombus
- • Left-sided valve
- • Contraindication to thrombolysis
- Operative mortality 10-15%
- (higher if emergent)
07Action Follow-Up & Prevention
Long-term management
- SURVEILLANCE:
- • Serial TEE until thrombus resolved
- • Regular INR monitoring
- • Annual TTE for gradients
- PREVENTION:
- • Strict anticoagulation adherence
- • INR self-testing if available
- • Patient education critical
08Outcome Thrombus Resolved / Valve Functional
Continue lifelong anticoagulation monitoring
09Action Thrombolysis
When surgery not feasible
- REGIMEN (Class IIa):
- • tPA 10mg bolus + 90mg over 90min
- • OR alteplase 25mg over 6h, repeat PRN
- • Monitor with serial TEE
- CONTRAINDICATIONS:
- • Recent stroke (<2 weeks)
- • Active bleeding
- • Recent major surgery
- • Large mobile thrombus
- Embolic risk: 10-15%
- Path rejoins step 07Shared downstream outcome
- Path rejoins step 06Shared downstream outcome
10Action Non-Obstructive PVT
Anticoagulation optimization first
- SMALL THROMBUS (<10mm):
- • Optimize anticoagulation (IV UFH)
- • Target higher INR (3.0-4.0)
- • Low-dose aspirin
- • Repeat TEE in 1-4 weeks
- LARGER THROMBUS or symptomatic:
- • Consider low-dose thrombolysis
- • Or surgery
11Action Anticoagulation Optimization
For non-obstructive or post-treatment
- IV UFH bridge → warfarin
- Target INR 3.0-4.0 (higher)
- Low-dose aspirin 81mg
- INVESTIGATE CAUSE:
- • Non-compliance
- • Drug interactions
- • Dietary changes (vitamin K)
- ⚠️ DOACs CONTRAINDICATED
- in mechanical valves (RE-ALIGN)
- Path rejoins step 07Shared downstream outcome
- Path rejoins step 09Shared downstream outcome
Guideline Source
ACC/AHA 2020 Guideline for Management of Valvular Heart Disease
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Surgery vs thrombolysis decision influenced by local expertise
- Thrombolysis embolic risk 10-15%
- Higher thrombosis risk with older-generation mechanical valves
- DOAC contraindicated in mechanical valves (RE-ALIGN trial)
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Prosthetic Valve Thrombosis Management (ACC/AHA 2020)?
The Prosthetic Valve Thrombosis Management (ACC/AHA 2020) is a emergency clinical algorithm for Cardiothoracic Surgery. It provides a structured decision tree to guide clinical decision-making, based on ACC/AHA 2020 Guideline for Management of Valvular Heart Disease.
What guideline is the Prosthetic Valve Thrombosis Management (ACC/AHA 2020) based on?
This algorithm is based on ACC/AHA 2020 Guideline for Management of Valvular Heart Disease (DOI: 10.1161/CIR.0000000000000923).
What are the limitations of the Prosthetic Valve Thrombosis Management (ACC/AHA 2020)?
Known limitations include: Surgery vs thrombolysis decision influenced by local expertise; Thrombolysis embolic risk 10-15%; Higher thrombosis risk with older-generation mechanical valves; DOAC contraindicated in mechanical valves (RE-ALIGN trial). Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Prosthetic Valve Thrombosis Management (ACC/AHA 2020) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free